Claims for Patent: 11,324,741

Summary for Patent: 11,324,741

Title:	Methods for treating visceral fat conditions
Abstract:	Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
Inventor(s):	Tollefson; Gary D. (Indianapolis, IN)
Assignee:	Nalpropion Pharmaceuticals LLC (Morristown, NJ)
Application Number:	15/446,933
Patent Claims:	1. A method of improving markers of insulin resistance comprising administering to a person who has been identified or diagnosed as being in need thereof an amount of naltrexone or a pharmaceutically acceptable salt thereof in a range of about 4 mg to about 50 mg each day and an amount of bupropion or a pharmaceutically acceptable salt thereof in a range of about 100 mg to about 600 mg each day, wherein the improvement in markers of insulin resistance is greater than expected from weight loss alone. 2. The method of claim 1, wherein the amount of bupropion or a pharmaceutically acceptable salt thereof is about 400 mg, and the amount of naltrexone or a pharmaceutically acceptable salt thereof is about 32 mg. 3. The method of claim 1, wherein the amount of naltrexone or a pharmaceutically acceptable salt thereof and the amount of bupropion or a pharmaceutically acceptable salt thereof are administered together in a single dosage form. 4. The method of claim 1, wherein naltrexone or a pharmaceutically acceptable salt thereof is in a sustained-release form, and bupropion or a pharmaceutically acceptable salt thereof is in a sustained-release form. 5. A method of improving fasting blood glucose levels comprising administering to a person who has been identified or diagnosed as being in need thereof an amount of naltrexone or a pharmaceutically acceptable salt thereof in a range of about 4 mg to about 50 mg each day and an amount of bupropion or a pharmaceutically acceptable salt thereof in a range of about 100 mg to about 600 mg each day, wherein the improvement in fasting blood glucose is significantly greater than expected from naltrexone or bupropion alone. 6. The method of claim 5, wherein the amount of bupropion or a pharmaceutically acceptable salt thereof is about 400 mg, and the amount of naltrexone or a pharmaceutically acceptable salt thereof is about 32 mg. 7. The method of claim 5, wherein the amount of naltrexone or a pharmaceutically acceptable salt thereof and the amount of bupropion or a pharmaceutically acceptable salt thereof are administered together in a single dosage form. 8. The method of claim 5, wherein naltrexone or a pharmaceutically acceptable salt thereof is in a sustained-release form, and bupropion or a pharmaceutically acceptable salt thereof is in a sustained-release form. 9. The method of claim 5, wherein fasting blood glucose is reduced to less than about 110 mg/dL. 10. A method of improving triglyceride levels or high-density cholesterol levels comprising administering to a person who has been identified or diagnosed as being in need thereof an amount of naltrexone or a pharmaceutically acceptable salt thereof in a range of about 4 mg to about 50 mg each day and an amount of bupropion or a pharmaceutically acceptable salt thereof in a range of about 100 mg to about 600 mg each day. 11. The method of claim 10, wherein the amount of bupropion or a pharmaceutically acceptable salt thereof is about 400 mg, and the amount of naltrexone or a pharmaceutically acceptable salt thereof is about 32 mg. 12. The method of claim 10, wherein the amount of naltrexone or a pharmaceutically acceptable salt thereof and the amount of bupropion or a pharmaceutically acceptable salt thereof are administered together in a single dosage form. 13. The method of claim 10, wherein naltrexone or a pharmaceutically acceptable salt thereof is in a sustained-release form, and bupropion or a pharmaceutically acceptable salt thereof is in a sustained-release form. 14. The method of claim 10, wherein the method improves triglyceride levels and the improvement is greater than expected from naltrexone or bupropion alone. 15. The method of claim 10, wherein the method improves high-density cholesterol levels. 16. The method of claim 14, wherein triglyceride levels are reduced to less than about 150 mg/dL. 17. The method of claim 15, wherein the person is male and high-density cholesterol levels are increased to more than about 40 mg/dL. 18. The method of claim 15, wherein the person is female and high-density cholesterol levels are increased to more than about 50 mg/dL.